FI5842U1 - Farmaseuttinen annosmuoto, joka käsittää suuren määrän lääkerakeita - Google Patents

Farmaseuttinen annosmuoto, joka käsittää suuren määrän lääkerakeita

Info

Publication number
FI5842U1
FI5842U1 FI20020500U FIU20020500U FI5842U1 FI 5842 U1 FI5842 U1 FI 5842U1 FI 20020500 U FI20020500 U FI 20020500U FI U20020500 U FIU20020500 U FI U20020500U FI 5842 U1 FI5842 U1 FI 5842U1
Authority
FI
Finland
Prior art keywords
large number
dosage form
pharmaceutical dosage
drug granules
granules
Prior art date
Application number
FI20020500U
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Johannes Jan Platteeuw
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23131212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI5842(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of FIU20020500U0 publication Critical patent/FIU20020500U0/fi
Application granted granted Critical
Publication of FI5842U1 publication Critical patent/FI5842U1/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI20020500U 2002-11-14 2002-12-16 Farmaseuttinen annosmuoto, joka käsittää suuren määrän lääkerakeita FI5842U1 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/293,940 US7018658B2 (en) 2002-11-14 2002-11-14 Pharmaceutical pellets comprising tamsulosin

Publications (2)

Publication Number Publication Date
FIU20020500U0 FIU20020500U0 (fi) 2002-12-16
FI5842U1 true FI5842U1 (fi) 2003-07-03

Family

ID=23131212

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20020500U FI5842U1 (fi) 2002-11-14 2002-12-16 Farmaseuttinen annosmuoto, joka käsittää suuren määrän lääkerakeita

Country Status (23)

Country Link
US (1) US7018658B2 (pl)
EP (1) EP1562573B1 (pl)
JP (1) JP5405710B2 (pl)
AT (2) ATE323478T1 (pl)
AU (3) AU2002351451A1 (pl)
BE (1) BE1015435A4 (pl)
CA (1) CA2415840C (pl)
CH (1) CH696419A5 (pl)
CZ (1) CZ13341U1 (pl)
DE (2) DE60210828T2 (pl)
DK (2) DK1562573T3 (pl)
ES (1) ES2257589T3 (pl)
FI (1) FI5842U1 (pl)
FR (1) FR2847166B1 (pl)
GB (1) GB2395125B (pl)
HU (1) HUP0500832A3 (pl)
NL (1) NL1022151C2 (pl)
NO (1) NO20052860L (pl)
PL (1) PL206083B1 (pl)
PT (1) PT1562573E (pl)
SI (1) SI21394A2 (pl)
WO (2) WO2004043449A1 (pl)
ZA (1) ZA200503696B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1476138E (pt) * 2002-02-21 2012-02-14 Valeant Internat Barbados Srl Formulações de libertação modificada de pelo menos uma forma de tramadol
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
WO2005004851A1 (en) * 2003-07-01 2005-01-20 Krka, Tovarna Zdravil, D.D. Novo Mesto Tamsulosin core with a coating of polyvinylpyrrolidone and polyvinylacetate
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
AU2003286415A1 (en) * 2003-12-03 2005-06-24 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
KR100615952B1 (ko) * 2004-05-27 2006-08-28 한국화학연구원 서방형 약물 전달 시스템
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DK1618873T3 (da) * 2004-07-14 2007-10-08 Siegfried Generics Int Ag Granulat til kontrolleret frigivelse af tamsulosin, indeholdende alginat
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007017253A1 (de) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Orales präparat mit kontrollierter freisetzung eines benzolsulfonamids
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
KR100745515B1 (ko) * 2006-04-10 2007-08-02 주식회사 대웅제약 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법
WO2007131804A1 (en) * 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
WO2009047312A1 (en) * 2007-10-12 2009-04-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising tamsulosin
EP2047847A1 (en) * 2007-10-12 2009-04-15 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising tamsulosin
EP2373297A1 (en) * 2008-12-09 2011-10-12 Synthon B.V. Tamsulosin pellets for fixed dose combination
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
NO2736497T3 (pl) 2011-07-29 2018-01-20
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
WO2014203137A2 (en) 2013-06-21 2014-12-24 Wockhardt Limited Pharmaceutical compositions of tamsulosin or salts thereof
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
EP2949319A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
CZ2015225A3 (cs) * 2015-03-30 2016-10-12 Zentiva, K.S. Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN105287395A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种盐酸坦索罗辛缓释微丸及其制备方法
ES2933177T3 (es) 2016-03-31 2023-02-02 Hanmi Pharm Ind Co Ltd Preparación de cápsulas compuestas, que contienen tadalafilo y tamsulosina, y que tienen una estabilidad y una tasa de elución mejoradas
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
WO2023072872A1 (en) 2021-10-25 2023-05-04 Farmalíder, S.A. Tadalafil oral suspension

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
JPS61100526A (ja) * 1984-10-22 1986-05-19 Kyowa Hakko Kogyo Co Ltd 持続性ドパミン経黒剤
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
IE60311B1 (en) 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
JPH07316077A (ja) * 1994-05-20 1995-12-05 Sumitomo Pharmaceut Co Ltd 腸溶性コーティング用組成物
US6177430B1 (en) * 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
JP3154710B1 (ja) * 1999-08-09 2001-04-09 山之内製薬株式会社 下部尿路症治療剤
TR200102583T2 (tr) * 1999-08-09 2002-07-22 Yamanouchi Pharmaceutical Co., Ltd. Alt idrar yolları semptomlarının tedavisine yönelik farmasötik bileşim.
JP2003508422A (ja) * 1999-09-02 2003-03-04 ノストラム・ファーマスーティカルズ・インコーポレイテッド 放出制御ペレット製剤
US6368628B1 (en) 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
RU2311903C2 (ru) * 2001-11-07 2007-12-10 Синтон Б.В. Таблетки тамзулосина
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin

Also Published As

Publication number Publication date
HUP0500832A3 (en) 2009-12-28
GB2395125A (en) 2004-05-19
DE60210828D1 (de) 2006-05-24
CZ13341U1 (cs) 2003-06-02
NO20052860D0 (no) 2005-06-13
AT6542U1 (de) 2003-12-29
WO2004043448A1 (en) 2004-05-27
US7018658B2 (en) 2006-03-28
CA2415840A1 (en) 2004-05-14
AU2003200059B2 (en) 2008-07-03
JP5405710B2 (ja) 2014-02-05
JP2006508960A (ja) 2006-03-16
US20040096502A1 (en) 2004-05-20
PT1562573E (pt) 2006-07-31
ZA200503696B (en) 2006-08-30
PL206083B1 (pl) 2010-06-30
BE1015435A4 (nl) 2005-04-05
WO2004043449A1 (en) 2004-05-27
CA2415840C (en) 2008-11-18
SI21394A2 (sl) 2004-06-30
AU2003200059A1 (en) 2004-06-03
AU2003288083A1 (en) 2004-06-03
ATE323478T1 (de) 2006-05-15
FIU20020500U0 (fi) 2002-12-16
EP1562573A1 (en) 2005-08-17
EP1562573B1 (en) 2006-04-19
FR2847166B1 (fr) 2005-06-10
GB0229021D0 (en) 2003-01-15
DK200300005U3 (da) 2003-04-25
AU2002351451A1 (en) 2004-06-03
NL1022151C2 (nl) 2004-05-18
ES2257589T3 (es) 2006-08-01
FR2847166A1 (fr) 2004-05-21
GB2395125B (en) 2007-06-06
DK1562573T3 (da) 2006-08-21
PL357856A1 (pl) 2004-05-17
CH696419A5 (de) 2007-06-15
DE20219293U1 (de) 2003-06-05
HUP0500832A2 (en) 2007-07-30
NO20052860L (no) 2005-08-10
DE60210828T2 (de) 2006-10-19

Similar Documents

Publication Publication Date Title
FI5842U1 (fi) Farmaseuttinen annosmuoto, joka käsittää suuren määrän lääkerakeita
DK1467789T3 (da) Lægemiddeldispenser
DK1545662T3 (da) Lægemiddelindgivelsessystem
NO20030627L (no) Hydrogel-drevet medikament doseringsform
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
ATE320799T1 (de) Retardierte, orale, pharmazeutische darreichnungsformen mit tramadol
DE60333294D1 (de) Kontrollierte verabreichung von arzneien
IS7946A (is) Lyf
IL166286A0 (en) Multicomponent pharmaceutical dosage form
DE60308372D1 (de) Dosierungsverabreichungsvorrichtung
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
ZA200701059B (en) Pharmaceutical dosage forms comprising a low-solubllity drug and a polymer
NO20044322L (no) Benzoksanon-avledede forbindelser, deres fremstilling og anvendelse som medikament
HK1091404A1 (en) Pharmaceutical oral dosage form comprising a non-steroidal anti- inflammatory drug, and having good palatability
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
DE60321572D1 (de) Transdermales arzneimittelverabreichungssystem
AU2003257102A8 (en) Pharmaceutical dosage form comprising a sulfite compound
NO20043633L (no) Oral doseringsform for kontrollert medikamentfrigivning
FR2820311B3 (fr) Distributeur de medicament portatif
IS7581A (is) Lyfjasamsetning
NL1023797A1 (nl) Farmaceutische doseringsvorm die zwangerschapsvriendelijke onderscheidingstekens draagt.
DE60328787D1 (de) Pharmazeutische salze von reboxetin
ITMI20020921A1 (it) Dispositivo per la sommistrazione di farmaci
DE10393889D2 (de) Medikament-Dosimeter-Kombipackung
UA8582S (uk) Ємність-туба для фармацевтичного засобу

Legal Events

Date Code Title Description
MDU Request for invalidation filed

Opponent name: ZENTIVA A.S.

MDU Request for invalidation filed

Opponent name: ZENTIVA A.S.

RFU Appeal filed
FCKU Appeal rejected

Free format text: UTILITY MODEL REVOCATED